September 21, 2016

No Image

U.S. Approves Export Of Boeing And Airbus Planes To Iran

An Iran Air Boeing 747 passenger plane sits on the tarmac of the domestic Mehrabad airport in the Iranian capital Tehran in 2013. Behrouz Mehri /AFP/Getty Images hide caption

toggle caption Behrouz Mehri /AFP/Getty Images

The U.S. Treasury Department has granted permission to Boeing and Airbus to export commercial planes to Iran, a Treasury spokesperson told NPR. The government has approved a deal — not yet finalized — for Boeing to sell IranAir 80 commercial passenger aircraft.

Thumbs-up from the Treasury is a major step forward on a key portion of last year’s deal between Iran and six world powers including the U.S., in which Iran agreed to curb its nuclear program in exchange for relief from decades-long sanctions. That relief officially started in January, as we reported.

“These licenses contain strict conditions to ensure that the planes will be used exclusively for commercial passenger use and cannot be resold or transferred to a designated entity,” the Treasury spokesperson said.

Boeing and Iran reached a $20 billion provisional agreement in late June for 80 aircraft, as NPR’s Jackie Northam reported.

Since then, the Treasury has “spent months scrutinizing the deal to see what technology will be used on the planes, and whether anyone remaining on a U.S. sanctions list is involved in the deal,” Jackie said.

She added that this marks the first time that Boeing has sold planes to Iran since its 1979 revolution. Jackie reports, “There is ferocious competition between Boeing and Airbus, and a good chance Boeing would be locked out of the Iranian market for decades if it didn’t get this approval.”

The new aircraft are a major step toward modernizing and expanding “the country’s elderly fleet, held together by smuggled or improvised parts after years of sanctions,” as Reuters reported.

The Treasury also granted Boeing’s competitor Airbus a license to sell 17 aircraft to IranAir, as Jackie reported. “Even though Airbus is based in Europe, it needs U.S. approval because its planes contain sophisticated technological equipment made in America. That includes the computers and navigational equipment.”

Both companies received the green light to sell a mix of wide-body and single aisle jets, Jackie said.

She has reported that this deal is seen as an important test case for doing business with Iran, including big questions on financing:

“Commercial aircraft are one of the very few products U.S. companies are allowed to sell to Iran. Even so, a deal has to be done without using American dollars or the U.S. financial system. This creates a problem even for international companies wanting to sell to Iran because most foreign banks have partnerships with American banks.

“[Former Treasury official Elizabeth] Rosenberg says that’s why all eyes are on Boeing to see if it can find innovative ways to pick through this financial minefield.”

The deals are also likely to “test conservative opposition” to the nuclear agreement in both the U.S. and Iran, as Reuters reported. In the U.S., many Republican lawmakers are against selling Iran planes, as are some conservatives in Iran.

Let’s block ads! (Why?)


No Image

Mylan CEO Claims EpiPens Aren't As Profitable As Everyone Thinks

Heather Bresch, CEO of Mylan Pharmacueticals, will face lawmakers’ questions Wednesday about the company’s steep price hikes for the company’s life-saving EpiPen auto-injector. Dale Sparks/AP hide caption

toggle caption Dale Sparks/AP

The drug company that makes the EpiPen says it isn’t nearly as profitable as many people assume it is.

At least that’s the message Mylan NV CEO Heather Bresch will try to deliver to members of Congress today.

Bresch, who is scheduled to testify before the House Oversight and Government Reform Committee, is expected to tell lawmakers that the company earns $100 profit on each two-pack of EpiPen auto-injectors, even though they carry a $600 price tag.

“The misconception about our profits is understandable, and at least partly due to the complex environment in which pharmaceutical prices are determined,” Bresch says in prepared testimony. “The pricing of a pharmaceutical product is opaque and frustrating, especially for patients.”

Bresch says it costs the company about $69 to make two EpiPens, and after rebates and fees, Mylan receives $274 per EpiPen pack. She says other, unnamed costs absorb an additional $105, leaving $100 in profit for the company.

While the company apparently is looking to use the analysis to downplay its profits, analysts say the margin is still quite high.

Ronny Gal, a pharmaceutical industry analyst at the investment firm Sanford Bernstein, says Bresch’s numbers mean Mylan makes a 40 percent profit margin on the device.

The EpiPen is a long, plastic tube that automatically injects a dose of epinephrine — or adrenaline — into a person’s thigh to stop an allergic reaction. It’s easy to use and portable.

Mylan bought rights to the EpiPen in 2008 and launched an aggressive marketing and awareness campaign. That effort has made the so-called auto-injector a must-have for anyone with a serious allergy — perhaps to bee stings or tree nuts — that may trigger anaphylaxis, a life-threatening reaction in which the airways swell and close.

The company has come under fire in recent months, however, because it raised the price of the device, which has been available for decades, more than 500 percent.

The wholesale price of a single pen was about $47 in 2007, and it rose to $284 this summer, according to Richard Evans, a health care analyst at SSR. But consumers can no longer buy a single pen, so the retail price to fill a prescription today at Walgreens is about $634, according to GoodRX.

Mylan has tried to quell the criticism first by offering customers a coupon worth up to $300 to offset the price of the device, and then announcing it would bring a generic version of the EpiPen to market for half the retail price.

In addition to the investigation by the House Oversight committee, at least three senators have also called for investigations into Mylan’s pricing practices. Sens. Charles Grassley, R-Iowa, and Richard Blumenthal, D-Conn., have sent letters to Mylan demanding an explanation for the increase.

Mylan responded with a letter that Grassley, in a press release, said was “incomplete.”

Sen. Amy Klobuchar, D-Minn., has asked the Federal Trade Commission to investigate whether Mylan has violated antitrust laws in its marketing of the EpiPen.

And the Senate Finance Committee is reviewing the rebates that Mylan offered to the Center for Medicare and Medicaid Services.

In her testimony, Bresch says the company did not intend for its price hikes to hurt patients.

“Looking back, I wish we had better anticipated the magnitude and acceleration of the rising financial issues for a growing minority of patients who may have ended up paying the full [Wholesale Acquisition Cost] price or more,” she says. “We never intended this.”

Let’s block ads! (Why?)